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The aim of this study was to evaluate the bioequivalence of two commercial long-acting 
formulations based on oxytetracycline (OTC) hydrochloride between the reference for-
mulation (Terramycin LA, Pfizer) and a test formulation (Cyamicin LA, Fort Dodge Saude 
Animal). Both formulations were administered in a single intramuscular route at a dose 
of 20 mg OTC/kg of body weight in clinically healthy bovines. The study was carried 
out according to a one-period parallel design. Plasma samples were analyzed by high- 
pressure liquid chromatography. The limit of quantitation was 0.050 μg/mL with an accu-
racy of 101.67% with a coefficient of variation of 13.15%. Analysis of variance and 90% 
confidence interval tests were used to compare the bioavailability parameters (maximum 
plasma concentration, Cmax, and the area under the concentration-versus-time curve 
extrapolated to infinity, AUC0–∞) of both products. In the case of the time to maximum 
concentration (Tmax), non-parametric tests based on Wilcoxon’s signed rank test were 
preferred. The comparison of the mean AUC0–∞ values did not reveal any significant 
differences (311.40 ± 93.05 μg h/mL and 287.71 ± 45.31 μg h/mL, respectively). The 
results were similar for the Tmax (3.58 ± 0.90 h versus 3.42 ± 0.51 h). However, when 
comparing the mean Cmax some significant differences were found (8.73 ± 3.66 μg/mL 
and 10.43 ± 3.84 μg/mL, respectively). The 90% confidence intervals for the ratio of 
AUC0–∞ and Tmax values for the reference and test product are within the interval 80–125%, 
but the 90% confidence intervals for the ratio of Cmax falls outside the proposed interval. It 
was concluded that Cmax of test product are not within the 20% of those of the reference, 
thus suggesting that test OTC is not bioequivalent to the reference formulation.
Keywords: oxytetracycline, pharmacokinetics, aUc, Cmax, Tmax, bioequivalence, bovines
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inTrODUcTiOn
The determination of the bioequivalence of veterinary drug 
formulations has become an increasingly important issue for 
both the European Union and the United States of America. 
Bioequivalence determination guidelines have been established 
by authorities of both regulatory bodies. For the American 
guideline, “two products are considered to be bioequivalent when 
they are equally bioavailable; that is, equal in the rate and extent 
to which the active ingredients(s) or therapeutic ingredient(s) 
is (are) absorbed and become(s) available at the site(s) of drug 
action” (1, 2). European guideline affirms that “bioequivalence 
exists between veterinary medicinal products or between routes 
of administration if, under identical and appropriate experimen-
tal conditions, the bioavailability of the active ingredient differs 
within acceptable limits” (3). In other words, both definitions 
state that equivalent rate and extent of absorption will lead to 
same plasma drug concentration–time profiles and, therefore, 
essentially the same magnitude of therapeutic or toxic effects.
The goal of the bioequivalence trial is to demonstrate that, with 
controlled risk to the patient, two formulations are bioequivalent 
and, therefore, the practitioner may use them interchangeably.
The determination of drug product bioequivalence is based on 
a statistical comparison of selected pharmacokinetic parameters 
of the two formulations of the same drug where the differences in 
rate and extent of drug absorption are shown to be no more than 
±20% with a 90% degree of confidence.
“In vivo” experiments are the best way to compare the bioavail-
ability of formulations with theoretically similar effects. In general 
terms, two formulations are compared, the new formulation (test 
formulation) versus a reference formulation efficacy of which has 
been clinically determined. According to the guidelines of the 
EMEA (3), the pharmacokinetic parameters compared between 
reference and test formulation in bioequivalence studies after 
a single dose are the area under the plasma concentration time 
(Cpt) curve to last concentration (AUC0–t) or the area under the 
Cpt curve extrapolate to infinity (AUC0–∞), the peak maximum 
plasma concentration (Cmax), and the time to maximum concen-
tration (Tmax). Non-compartmental analysis methods should be 
used for determination of the pharmacokinetic parameters in 
bioequivalence studies. If these three parameters deviate within 
the acceptance range, then the test formulation is considered to 
be bioequivalent to the reference product.
Briefly, the width of the confidence interval is determined by 
the within subject variance (between subject variance for parallel 
group studies) and the number of subjects in the study. In gen-
eral, the confidence interval for untransformed data should be 
80–120% (the confidence interval should lie within ±20% of the 
mean of the reference product). For logarithmically transformed 
data, the confidence interval is generally 80–125%.
In veterinary medicine, oxytetracycline (OTC) as well as 
the other major tetracyclines, are widely used mainly to treat 
respiratory, gastrointestinal, skin, locomotive organs, and genito-
urinary bacterial infections, as well as systemic infections and 
sepsis (4).
Oxytetracycline is one of the cheapest classes of tetracycline 
antibiotics available, and this is due to modern manufacturing 
processes. Such conditions make it particularly attractive for its 
use in developing countries. The molecule has been available for 
veterinary medicine for the last half-century.
Due to the difficulties that daily OTC injections represent, 
long-acting (LA) alternatives were developed to achieve fast 
and high blood levels and to provide greater effective plasma 
concentrations during several days (5–7). An ideal OTC for-
mulation for cattle should have some characteristics, such as 
the ability to maintain antimicrobial concentrations in tissues 
above the bacterial minimum inhibitory concentration for a 
long period of time, be easy to administrate, and with minimal 
tissue irritation or damage. Consequently, parenteral LA injec-
tions are used as an alternative for the therapy of diseases that 
normally require several daily parenteral treatments to provide 
sustained concentrations of the antibiotic at the site of infection. 
The formulation provides prolonged circulating antibacterial 
concentration of the active agent, without the profile produced 
by repeated injections that may lead to the concentration of the 
agent in the blood and tissue falling below effective values. Such 
preparations have been particularly popular in cattle and swine 
because of the convenience of a single injection (4, 5, 8). Licensed 
20 and 30% formulations of OTC have persistent actions because 
of the high strength and high dosage used (20 or 30  mg/kg), 
leading to sustained absorption from the reservoir site at the 
intramuscular injection.
Many OTC pharmacokinetic studies have been conducted in 
cattle. For generic medicinal products, the purpose of establish-
ing bioequivalence is to demonstrate equivalence in pharmacoki-
netic parameters between the generic medicinal product (test 
product) and a reference one (3). Consequently, bioequivalence 
studies are important for the development of new pharmaceutical 
formulations (9).
The purpose of this study was to demonstrate the bioequiva-
lence of two LA commercial OTCs, a test formulation (Cyamicin 
20% LA) and the reference formulation (Terramycin 20% LA) 
after intramuscular administration to bovine.
MaTerials anD MeThODs
chemicals and reagents
Oxytetracycline hydrochloride of high purity (>95%) was pur-
chased from Sigma Aldrich Chemicals and high-performance 
liquid chromatography (HPLC) grade solvents were obtained 
from J.T. Baker®.
Drugs
Two commercial products of OTC, containing 200  mg of 
OTC hydrochloride were compared. A reference formulation 
(Terramycin 20% LA, Pfizer) and a test formulation (Cyamicin 
20% LA, Fort Dodge Saude Animal) were used. In order to con-
firm OTC concentrations, the two formulations were previously 
analyzed.
animals
Twenty four young castrated male Aberdeen Angus bovines 
weighing 150–280 kg and aged between 6 and 12 months were 
used in this study. Animals were clinically evaluated to assure 
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satisfactory health status prior to the beginning of the study and 
were identified with plastic numbered ear-tags.
experimental Design
Animals were divided into two groups (group A and group B) 
of 12 bovines each, according VICH guidelines (VICH GL 
52  –  Bioequivalence, 2015) (10). The animals were ranked by 
weight and allocated by Greek guard to one of the two groups, 
after random allocation of the first animal. The scale was a digital 
Ezy-weight, made in New Zealand.
Dosage way and route of administration were done fol-
lowing the label instructions of each antibiotic. Only one 
treatment was carried out per bovine; thus, the study was 
designed as a one-period parallel study. Parallel designs do 
not need a washout period between treatments and they are 
often used for bioequivalence studies conducted in patients 
or for drugs with a long half-life where crossover studies are 
difficult or impossible to perform. If the bioequivalence study is 
problematic, single-dose parallel designs can be an alternative 
choice, because it is easy to organize, easy to analyze, and easy 
to interpret. The intramuscular (i.m.) injection was applied on 
the gluteal area.
 – Animals of group A were given a single i.m. dose of 20 mg/kg 
of the reference (R) product (Terramycin LA, Pfizer).
 – Animals of group B received the test (T) formulation (Cyamicin 
LA, Fort Dodge) at the same dose and by the same route.
The 24 animals were housed in a grass paddock. Feeding was on 
natural pasture and water was available ad libitum. The protocol 
followed the “Guide for the Care and Use of Agricultural Animals 
in Agricultural Research and Teaching” (Federation of Animal 
Science Societies, FASS) and was approved by the Experimental 
Ethics Committee of the Faculty of Veterinary Science, UNLP, 
Argentina.
Animals were sampled during the following 5  days after 
the OTC application. Blood samples were obtained from each 
animal from the jugular vein at the following post-treatment 
hours: 1, 2, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, 48, 60, 72, 96, and 
120 to measure the level of active ingredient. Bleeding was 
done with 10  mL plastic disposal heparinized syringes and 
21Gx11/2″ gage. Plasma was obtained by centrifugation and 
each tube was properly identified and was stored at −20°C 
until assayed.
Oxytetracycline was assayed by HPLC. Pharmacokinetics and 
comparative bioavailability were determined.
Oxytetracycline assay
Plasma samples were analyzed for OTC determination follow-
ing an analytical method validated at LEFyT (SOP: OTC-PL- 
VMA-12/05).
Oxytetracycline was assayed by HPLC with UV detection. 
For this, 0.1 mL plasma samples were deproteinized by adding 
0.2  mL of acetonitrile and vigorously mixing for 5  min. After 
centrifugation of the samples for 10  min, the supernatant was 
evaporated to dryness at 45°C under nitrogen stream. The residue 
was reconstituted with 100% of mobile phase and then a 50 μL 
aliquot was injected directly into the HPLC system.
The chromatographic system consisted of an isocratic pump 
(Gilson Inc. 307), an automatic injector (Gilson Inc. 234) and a 
UV-VIS detector (Gilson Inc. 155) set at a wavelength of 254 nm 
and an octadecylsilane column (Luna C18, 4.6 mm × 150 mm, 
5  μm; Phenomenex, Torrance, CA, USA). The sample was 
eluted with a mixture of 0.05 M phosphate buffer (pH 4.5) and 
acetonitrile (85:15, v/v) at a flow rate of 1.5 mL/min and at room 
temperature. The calibration curve from the standard samples 
was linear over the concentration range of 0.05–10 μg/mL.
Precision of the system
One standard solution containing 1 μg/mL of OTC was prepared 
and the precision of the system was evaluated after the place-
ment of 20 injections in the chromatographic system. Thereby, 
the efficiencies of the column and of the system were evaluated. 
After 20 injections a coefficient of variation (CV) of 8.59% was 
determined.
calibration and Validation
Assay was validated by measuring concentrations of known 
amounts of OTC in plasma of cattle. Linearity, precision, accu-
racy, recovery, and specificity were determined (n = 6).
Linearity of Standard Curves
The ratio between different concentrations was determined. 
Calibration curve was obtained for OTC (concentrations ranging 
between 0.05 and 10 μg/mL).
Precision and Accuracy
The inter-day precision was determined to estimate the run-to-
run extraction and chromatographic variation in the method. 
Inter-day variation was measured during three (3) consecutive 
working days for plasma samples. Precision was expressed as 
%CV and accuracy as %ER (11, 12).
Accuracy is defined as the extent to which the experimental 
values agree with the true values. Accuracy of the method was 
determined by the differences between desired and calculated 
concentration results divided by desired concentration, and 
expressed as the relative error (% RE) (11, 12).
Lower Limit of Quantitation
The lower limit of quantitation (LLOQ) was calculated (n = 12) 
as the lowest drug concentration on the standard curve that could 
be quantitated with CV and relative error not exceeding 20%, and 
recovery between 20 and 80% of nominal value (11, 12).
Pharmacokinetic and statistical analysis
Pharmacokinetic analyses were performed using WinNonlin 
Professional version 6.4 (Pharsight Corp.) software. The linear 
trapezoidal rule was used to calculate the AUC0–last. In addition, 
the elimination rate constant (kel) determined from the terminal 
slope by log-linear regression, T1/2, and AUC0–∞ calculated as 
the addition of AUC0–last and Clast/kel, were determined for the 
analysis.
The one-way analysis of variance (ANOVA) for parallel design 
was used to assess the effect of formulations on the raw (untrans-
formed) and logarithmically transformed data of AUC0–∞, Tmax 
TaBle 1 | intra-day recovery, precision, and accuracy.
Desired 
(μg/ml)
calculated 
(μg/ml)
recovery 
(%)
Mean sD Precision  
(% cV)
accuracy 
(% re)
0.05 0.05 100.00
0.05 0.04 80.00
0.05 0.06 120.00
0.05 0.05 100.00
0.05 0.05 100.00
0.05 0.05 100.00 100.00 12.65 12.65 0.00
0.25 0.2 80.00
0.25 0.26 104.00
0.25 0.2 80.00
0.25 0.22 88.00
0.25 0.2 80.00
0.25 0.26 104.00 89.33 11.78 13.18 −12.00
5 4.14 82.80
5 4.12 82.40
5 5.13 102.60
5 4.22 84.40
5 5.08 101.60
5 3.82 76.40 88.37 10.98 12.43 −11.60
10 8.26 82.60
10 8.54 85.40
10 7.41 74.10
10 8.47 84.70
10 10.93 109.30
10 8.91 89.10 87.53 11.78 13.46 −12.5
% CV = (SD/calculated concentration) × 100; % RE = (calculated 
concentration − desired concentration)/(desired concentration × 100).
FigUre 1 | calibration curve corresponding to OTc standard.
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and Cmax according VICH GL52 (Bioequivalence, August 2015) 
(10). In the case of Tmax, non-parametric tests based on Wilcoxon’s 
signed rank test were preferred (13). Parametric 90% confidence 
intervals based on the ANOVA of the mean Test/Reference ratios 
of AUC0–∞, and Cmax were computed under the assumption of 
multiplicative model using log-transformed data. Confidence 
intervals were determined by the method of Westlake (14).
resUlTs
assay linearity
This assay exhibited a linear dynamic range between 0.05 and 
10 μg/mL with r2 value >0.999. A linear relationship was obtained 
across one dynamic range, as determined for the plasma spiked 
curves shown in Figure 1.
limit of Detection
The limit of detection (LOD) is the smallest detectable but not 
quantifiable quantity of analyte. It was estimated by means of 
the analysis of 20 aliquots of control plasma (free of antibiotic). 
The noise of the base-line was measured; the average and the SD 
were calculated. The LOD corresponds to three of those SDs, 
which in this case allowed to detect levels of 0.013 μg/mL with a 
recovery of >85%.
intra-Day and inter-Day accuracy 
and Precision
To assess the inter-day (over 3 days) assay accuracy and precision, 
three sets of plasma samples were spiked with OTC at 0.05, 0.25, 
5, and 10 μg/mL concentrations.
To determine the intra-day accuracy and precision, six 
replicates at each four concentrations were analyzed along with 
duplicate standard calibration curves prepared from two separate 
stock solutions.
The intra-day and inter-day variation recovery, precision, and 
accuracy of the method are illustrated in Tables 1 and 2, respec-
tively. The mean recovery was within the range of 85–115%, and 
precision and accuracy for the 0.25, 5.00, and 10.00 μg/mL were, 
respectively, ≤15 and ±15%.
specificity
Six different samples from control plasma (free of antibiotics) 
and six plasma samples loaded with OTC were analyzed by 
HPLC and the corresponding chromatograms were compared. 
With this technique, no interferences in the retention time 
(3.85 ± 0.14 min) for OTC were found (Figure 2).
lower limit of Quantitation
The lower limit of quantitation was 0.050 μg/mL with a recovery 
of 103.33%, and a precision and accuracy, respectively, ≤20 
and ±20%.
Pharmacokinetic analysis
The mean ± SD OTC plasma concentration–time profiles after 
the intramuscular administration of each formulation (R and T) 
to bovines are presented in Figure 3, whereas the intramuscular 
pharmacokinetic data for Terramycin LA and Cyamicin LA, are 
presented in Table 3.
Oxytetracycline plasma concentrations evolved following 
known features for 20% formulations. Maximum plasma con-
centrations (Cmax) of 8.73 ± 3.66 and 10.43 ± 3.84 μg/mL were 
obtained for R and T formulations, respectively. Both formula-
tions reached the Cmax between 3 to 4 h. The terminal elimination 
half-lives (T½λ) of OTC were 36.88 ± 11.50 h and 32.61 ± 5.14 h 
after administration of Terramycin LA and Cyamicin LA, respec-
tively (Table 3).
TaBle 2 | inter-day recovery, precision, and accuracy.
Desired 
(μg/ml)
Day 1  
(calculate)
%  
recovery
Day 2 
(calculate)
% 
recovery
Day 3 
(calculate)
%  
recovery
Mean (% 
recovery)
sD (% 
recovery)
%cV (% 
recovery)
accuracy 
(%re)
0.05 0.05 100.00 0.06 120.00 0.04 84.00 101.33 18.04 17.80
0.05 0.04 80.00 0.05 100.00 0.06 116.00 98.67 18.04 18.28
0.05 0.06 120.00 0.05 100.00 0.06 120.00 113.33 11.55 10.19
0.05 0.05 100.00 0.05 100.00 0.06 120.00 106.67 11.55 10.83
0.05 0.05 100.00 0.06 120.00 0.06 120.00 113.33 11.55 10.19
0.05 0.05 100.00 0.04 80.00 0.04 80.00 86.67 11.55 13.32
Mean 0.05 100.00 0.05 103.33 0.05 106.67 103.33
SD 0.01 12.65 0.01 15.06 0.01 19.21 10.15
CV% 12.65 12.65 14.57 14.57 18.01 18.01 9.82 0.00
0.25 0.20 80.00 0.23 92.00 0.28 112.00 94.67 16.17 17.08
0.25 0.26 104.00 0.23 92.00 0.24 96.00 97.33 6.11 6.28
0.25 0.20 80.00 0.22 88.00 0.24 96.00 88.00 8.00 9.09
0.25 0.22 88.00 0.21 84.00 0.25 100.00 90.67 8.33 9.18
0.25 0.20 80.00 0.23 92.00 0.23 92.00 88.00 6.93 7.87
0.25 0.26 104.00 0.24 96.00 0.24 96.00 98.67 4.62 4.68
Mean 0.22 89.33 0.23 90.67 0.25 98.67 92.89
SD 0.03 11.78 0.01 4.13 0.02 7.00 4.67
CV% 13.18 13.18 4.56 4.56 7.10 7.10 5.03 −8.00
5 4.14 82.80 4.72 94.40 4.18 83.6 86.93 6.48 7.45
5 4.12 82.40 4.21 84.20 3.98 79.6 82.07 2.32 2.82
5 5.13 102.60 5.08 101.60 4.01 80.20 94.80 12.65 13.35
5 4.22 84.40 4.87 97.40 4.87 97.40 93.07 7.51 8.06
5 5.08 101.60 3.95 79.00 3.98 79.60 86.73 12.88 14.85
5 3.82 76.40 4.14 82.80 4.21 84.20 81.13 4.16 5.13
Mean 4.42 88.37 4.50 89.90 4.21 84.10 87.46
SD 0.55 10.98 0.46 9.11 0.34 6.82 5.57
CV% 12.43 12.43 10.14 10.14 8.11 8.11 6.37 −12.40
10 8.26 82.60 8.82 88.20 8.09 80.90 83.90 3.82 4.55
10 8.54 85.40 8.78 87.80 8.99 89.90 87.70 2.25 2.57
10 7.41 74.10 10.93 109.30 8.77 87.70 90.37 17.75 19.64
10 8.47 84.70 10.37 103.70 8.93 89.30 92.57 9.91 10.71
10 10.93 109.30 9.23 92.30 9.21 92.10 97.90 9.87 10.08
10 8.91 89.10 8.97 89.70 8.94 89.40 89.40 0.30 0.34
Mean 8.75 87.53 9.52 95.17 8.82 88.22 90.31
SD 1.18 11.78 0.91 9.09 0.39 3.85 4.72
CV% 13.46 13.46 9.56 9.56 4.37 4.37 5.23 −9.70
% CV = (SD/calculated concentration) × 100; % RE = (calculated concentration − desired concentration) / (desired concentration × 100).
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Bioequivalence analysis
The bioavailability of the Test product (Cyamicin L.A) relative 
to the Reference product (Terramycin L.A) was compared 
on the basis of the Log-transformed and untransformed 
study data. Differences between the R and T products were 
statistically evaluated by means of confidence intervals. Cmax, 
Tmax, and AUC0–∞ were analyzed by ANOVA. The criterion for 
product bioequivalence requires for Cmax, Tmax, and AUC0–∞ that 
the 90% confidence intervals about the difference in product 
means (test minus reference values) be within ±20% of the 
reference mean.
Tables 4 and 5 displays the statistic ANOVA comparison for 
log-transformation and untransformed data and the Westlake’s 
90% CI interval, respectively. Using this criterion, the test product 
did not demonstrate bioequivalence with the reference product. 
The parameters Tmax and AUC0–∞ of the test formulation were not 
significantly different from the reference formulation. However, 
in the case of Cmax, T product presented a significantly higher value 
compared to R, which exceeded the bioequivalence criterion.
DiscUssiOn
The analytical method showed good specificity, sensitivity, linear-
ity, precision, and accuracy for the quantitation of OTC in plasma 
samples, thus allowing its use in bioequivalence assays.
The average plasma profile obtained for the reference 
(Terramycin LA, Pfizer) and test (Cyamicin LA, Fort Dodge) 
products were similar, as well as the pharmacokinetic parameters.
The area under the concentration-versus-time curve (AUC) 
is the parameter that indicates the exposure to the drug in base 
to the fraction of the dose reaching the systemic circulation and 
systemic clearance of the drug. In our study, the area under the 
OTC curve extrapolate to infinity (AUC0–∞) was 311.40 ± 93.05 
and 287.71 ±  45.31 μg h/mL for R and T formulation, respec-
tively. These values were high; this makes sense due to the 
prolonged elimination slope. While AUC0–24 values were smaller 
(118.29 ± 45.46 and 131.15 ± 44.56 μg h/mL respectively) com-
pared to those reported by Craigmill et al. (15) in calves receiving 
the same dose of OTC LA (168 ± 14.6 μg h/mL), and with the 
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area under the curve calculated by Achenbach (16) which was 
256.73 μg  h/mL, both authors performed these assays on sera 
samples, while our study was conducted using plasma.
To determine if two formulations would yield the same 
efficacy behavior, their areas under the respective curves, their 
maximum concentrations, and the times at which the Cmax is 
reached, should be determined and compared statistically. If the 
differences among such parameters are not significant, the drugs 
are bioequivalent, but if the differences are significant, the for-
mulations are bioinequivalent. In the present work, these param-
eters were compared through ANOVA, since the populations 
were normal, using untransformed and log-transformed values. 
No significant differences were encountered for areas under the 
curves, and times to the maximum concentrations for the values 
found were inside the confidence intervals set by the European 
Union to determine bioequivalence. However, the maximum 
concentration (Cmax) of the test product (Cyamicin LA) was 
significantly higher than that of the reference formulation and 
exceeded the bioequivalence interval. These significant differ-
ences were found in the untransformed and the log-transformed 
methodologies and these values were outside the confidence 
intervals.
FigUre 2 | hPlc chromatograms (UV detector set at 254 nm). (a) Chromatogram of standard OTC solution (1 μg/mL); (B) chromatogram of control plasma 
sample (free of OTC) after extraction procedure; (c) chromatogram after extraction of plasma spiked with OTC (1 μg/mL); and (D) chromatogram after extraction of 
problem sample (animal 1 after 4 h OTC formulation administration).
7Mestorino et al. Oxytetracycline Bioequivalence Study
Frontiers in Veterinary Science | www.frontiersin.org June 2016 | Volume 3 | Article 50
FigUre 3 | semilogarithmic comparative curves (mean ± sD) of oxytetracycline plasma profiles obtained following intramuscular administration of 
both formulations to bovines. Small inserted figure: arithmetic comparative curves (0–24 h after each administration).
TaBle 3 | comparison of the pharmacokinetic parameters (mean ± sD) 
of the reference (Terramycin la) and test (cyamicin la) formulations 
at a single dose (20 mg/kg) administration to bovines.
Terramycin cyamicin
Parameter Unit Mean sD Mean sD
λ h−1 0.020 0.005 0.022 0.004
T½λ h 36.88 11.50 32.61 5.14
Cmax μg/mL 8.73 3.66 10.43 3.84
Tmax h 3.58 0.90 3.42 0.51
AUC0–∞ μg h/mL 311.40 93.05 287.71 45.31
AUC0–24 μg h/mL 118.29 45.46 131.15 44.56
λ, rate constant associated with the terminal elimination phase; T½λ, elimination half-
life; Cmax, maximum concentration; Tmax, time to reach maximum concentration; AUC0–∞, 
area under the concentration–time curve from 0 to infinity; AUC0–24, area under the 
concentration time curve from 0 to 24 h.
TaBle 4 | statistical comparison between the pharmacokinetic 
parameters obtained for Terramycin l.a (r) and cyamicin (T) by anOVa 
Test with log transformed and untransformed data.
Parameter reference Test anOVa anOVa (log)
AUC 311.40 ± 93.05 287.71 ± 45.31 >0.30 >0.30
Cmax 8.73 ± 3.66 10.43 ± 3.84 0.22 0.21
Tmax* 3.58 ± 0.90 3.42 ± 0.51 >0.30 >0.30
Tmax*: bioequivalence evaluation by Steinijans and Diletti’s non-parametric test. 
Arithmetic mean of individual differences = −1.66667E−01.
90% confidence interval (Test vs. Ref.) = 86.0–114.0% vs. mean Ref.
TaBle 5 | Westlake’s 90% interval calculated iteratively for log 
untransformed and transformed data.
Parameter reference Test Westlake, 
interval for 
untransformed 
90% (Usa)
Westlake, 
interval after 
ln-transformation 
90% (log) (cee)
AUC 311.40 ± 
93.05
287.71 ± 45.31 80.58–119.42% 85.89–114.11%
Cmax 8.73 ± 3.66 10.43 ± 3.84 60.13–139.87% 65.04–134.97%
Tmax 3.58 ± 0.90 3.42 ± 0.51 83.29–116.71% 86.28–113.72%
The results obtained with i.m. administration of OTC LA in 
this study for Cmax were similar to those of Ozdemir and Yildirim 
(17) who reported that Cmax was 8.02 μg/mL at 2.75 h. Although 
this was a study of the bioequivalence of two LA OTC formulations 
in sheep, the authors obtained similar results. They mentioned 
that the multivariate analysis, accomplished through ANOVA 
for pharmacokinetic parameters (after log-transformation of the 
data), showed no statistically significant differences between the 
two products for the parameters Cmax and AUC except between 
two periods and two groups for AUC. By contrast, much lower 
Cmax values of 4, 3.89 ± 1.48, and 5.7 ± 0.32 were reported in cat-
tle by Toutain and Raynaud (6), Mestorino et al. (5), and Kumar 
and Malik (18).
As a final conclusion, the formulations behaved similarly 
but were not bioequivalent, although Tmax and AUC fell within 
the bioequivalence criterion. In the case of Cmax, a parameter 
classically considered of importance regarding antimicrobial 
efficacy, the value obtained after administration of Cyamicin was 
statistically significantly higher. The 90% confidence interval of 
T/R was 65.04–134.97% for log-transformation Cmax. This interval 
is not included in the equivalence interval (80–125%), therefore, 
cannot be considered bioequivalent. The test product showed 
an extent of absorption appreciably larger than the reference 
product following administration of the same dose; therefore, 
suprabioavailability was found. Probably equivalent AUC and 
Cmax are achieved following administration of a lower dose of the 
test product as compared to the reference formulation. So could 
be expected that the two products will have similar systemic 
efficacy and safety although administered at different doses, but a 
new bioequivalence assay must be performed.
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